Stock GLPG GALAPAGOS NV
Add to a list
To use this feature you must be a member
Log inSign up

News Galapagos NV

Equities

GLPG

BE0003818359

Real-time Euronext Amsterdam
Other stock markets
 10:29:34 2024-04-19 am EDT 		5-day change 1st Jan Change
27.1 EUR -1.02% Intraday chart for Galapagos NV -4.91% -26.74%
Apr. 08 Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024 CI
Mar. 28 Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024
CI
Galapagos : Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
PU
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
GL
Galapagos : Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
PU
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
GL
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says
MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41
MT
Galapagos NV Announces Board Changes
CI
Galapagos : Galapagos benoemt Andrew Dickinson tot Niet-Uitvoerend, Niet-Onafhankelijk Bestuurder van haar Raad van Bestuur
PU
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
GL
Galapagos to Seek Acquisitions
CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024
Galapagos announces full year 2023 results and outlook for 2024
GL
Frontier Medicines Corporation announced that it has received $80.000001 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors
CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Galapagos presents at EBMT-EHA annual meeting 2024
GL
Galapagos presents at EBMT-EHA annual meeting 2024
AQ
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024
CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma
MT
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLPG Stock
  4. News Galapagos NV